Method Profile
A stepwise comparison translates cannabidiol and 7-hydroxycannabidiol inhibition data through basic, mechanistic static and PBPK models, then compares predictions with clinical observations.
Research assessment of metabolic interaction pathways and the effect of model structure on predicted substrate exposure.
Basic, mechanistic static and parent–metabolite PBPK models incorporating reversible and time-dependent CYP inhibition.
Evaluate static predictions, develop and assess the parent–metabolite PBPK model, refine inhibition parameters against clinical observations where required, and revisit the static predictions.
Inputs
In vitro inhibition parameters for cannabidiol and 7-hydroxycannabidiol; clinical pharmacokinetic and interaction observations.
Compare the magnitude and pathway pattern of predicted exposure changes across the three model levels.
Static and PBPK predictions are compared with clinical pharmacokinetic and drug-interaction observations.
Cannabidiol, its active metabolite, sensitive CYP substrates and available clinical datasets.
Basic and mechanistic static predictions versus PBPK estimates and clinical exposure changes.
The mechanistic static model predicted 3.6-, 4.1- and 2.2-fold increases for CYP1A2, CYP2C9 and CYP3A4 substrates. PBPK predictions were lower and identified CYP2C19 as the main interaction pathway.
A stepwise modeling study compared in vitro enzyme-inhibition signals with clinical pharmacokinetic observations. PBPK predictions were generally lower than mechanistic static estimates, with CYP2C19 emerging as the main interaction concern.
